Northern Trust Corp Increases Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Northern Trust Corp boosted its holdings in Accuray Incorporated (NASDAQ:ARAY) by 0.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 809,665 shares of the medical equipment provider’s stock after acquiring an additional 7,399 shares during the quarter. Northern Trust Corp owned 0.79% of Accuray worth $1,603,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ARAY. Susquehanna Fundamental Investments LLC bought a new stake in Accuray in the 4th quarter worth approximately $66,000. MetLife Investment Management LLC lifted its stake in shares of Accuray by 38.3% in the 4th quarter. MetLife Investment Management LLC now owns 48,234 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 13,370 shares during the period. Gabelli Funds LLC lifted its stake in shares of Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider’s stock worth $89,000 after purchasing an additional 5,000 shares during the period. Walleye Capital LLC purchased a new position in shares of Accuray in the fourth quarter worth approximately $300,000. Finally, Barclays PLC grew its position in Accuray by 7.6% during the fourth quarter. Barclays PLC now owns 226,812 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 15,993 shares during the period. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, May 21st.

Accuray Trading Down 0.6%

Shares of ARAY stock opened at $1.57 on Tuesday. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The stock has a fifty day simple moving average of $1.60 and a two-hundred day simple moving average of $1.89. The firm has a market capitalization of $161.73 million, a PE ratio of -31.40 and a beta of 1.30. Accuray Incorporated has a 52-week low of $1.28 and a 52-week high of $2.95.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The business had revenue of $113.24 million for the quarter, compared to analysts’ expectations of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, analysts predict that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.